Findings

What do systematic reviews say?

324 questions · 341 findings · 54 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 120 · 35.2%GRADE not reported 9 · 2.6%Very low 97 · 28.4%Low 80 · 23.5%Moderate 25 · 7.3%High 10 · 2.9%

Ultrasound‐assisted catheter‐directed thrombolysis plus standard intravenous heparinisation vs standard intravenous heparinisation

Quality of life Â · people with intermediate‐risk (submassive) APE

1 finding from 1 review

Catheter‐directed therapies for the treatment of high risk (massive) and intermediate risk (submassive) acute… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 59 participants
GRADE not reported

Zinc vs placebo

BMD Z score (total hip/femoral neck) · children and adults with β‐thalassaemia major and low bone mass

Summary of findings – zinc probably leads to higher BMD Z score (total hip/femoral neck) compared with placebo (moderate certainty).

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
MD 0.15 [0.11, 0.19]
1 study · 37 participants
Moderate

Zinc vs placebo

BMD Z score (lumbar spine) · children and adults with β‐thalassaemia major and low bone mass

Summary of findings – zinc probably leads to higher BMD Z score (lumbar spine) compared with placebo (moderate certainty).

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
MD 0.15 [0.1, 0.2]
1 study · 37 participants
Moderate

Zinc vs placebo

BMD Z score (wrist) · children and adults with β‐thalassaemia major and low bone mass

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Zinc vs placebo

Incidence of fractures · children and adults with β‐thalassaemia major and low bone mass

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Zinc vs placebo

Mobility · children and adults with β‐thalassaemia major and low bone mass

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Zinc vs placebo

Quality of life · children and adults with β‐thalassaemia major and low bone mass

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Zinc vs placebo

Adverse effects of treatment · children and adults with β‐thalassaemia major and low bone mass

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – denosumab vs placebo

BMD Z score (total hip/femoral neck) · adults with β‐thalassaemia and low bone mass

Summary of findings – denosumab showed no clear difference in BMD Z score (total hip/femoral neck) compared with placebo (low certainty).

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
MD 0.05
1 study · 63 participants
Low

Summary of findings – denosumab vs placebo

BMD Z score (lumbar spine) · adults with β‐thalassaemia and low bone mass

Summary of findings – denosumab showed no clear difference in BMD Z score (lumbar spine) compared with placebo (low certainty).

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 63 participants
Low

Summary of findings – denosumab vs placebo

BMD Z score (wrist) · adults with β‐thalassaemia and low bone mass

Summary of findings – denosumab showed no clear difference in BMD Z score (wrist) compared with placebo (low certainty).

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 63 participants
Low

Summary of findings – denosumab vs placebo

Incidence of fractures · adults with β‐thalassaemia and low bone mass

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – denosumab vs placebo

Mobility · adults with β‐thalassaemia and low bone mass

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – denosumab vs placebo

Quality of life · adults with β‐thalassaemia and low bone mass

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – denosumab vs placebo

Adverse effects of treatment · adults with β‐thalassaemia and low bone mass

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – strontium ranelate vs placebo

BMD Z score (total hip/femoral neck) · women with low bone mass and β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – strontium ranelate vs placebo

BMD Z score (lumbar spine) · women with low bone mass and β‐thalassaemia

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Very low

Summary of findings – strontium ranelate vs placebo

BMD Z score (wrist) · women with low bone mass and β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – strontium ranelate vs placebo

Incidence of fractures · women with low bone mass and β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Summary of findings – strontium ranelate vs placebo

Mobility · women with low bone mass and β‐thalassaemia

The review found no eligible studies for this question.

1 finding from 1 review

Treatment for osteoporosis in people with beta‐thalassaemia 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found